Alpha -Tocopherol Dl- Ascorbic Acid Calcium Format

證據等級: L5

預測適應症: 0 個

Multi-component Nutritional Supplement (Alpha-Tocopherol / Ascorbic Acid / Cholecalciferol / Cyanocobalamin / Doconexent / Folic Acid + 4 others): Repurposing Evaluation — Insufficient Data

One-Sentence Summary

This candidate is a 10-component nutritional supplement combination — including Vitamin E (DL-Alpha-Tocopherol), Vitamin C (Ascorbic Acid), Vitamin D3 (Cholecalciferol), Vitamin B12 (Cyanocobalamin), DHA (Doconexent), Folic Acid, Iron (Ferrous Asparto Glycinate), Calcium Formate, Magnesium Oxide, and Vitamin B6 (Pyridoxine) — which resembles a prenatal or comprehensive maternal supplement formulation.

However, this evaluation cannot be completed in the standard format: the TxGNN pipeline returned no predicted indications, no original indication is registered, and the product holds no US market authorization. The evidence pack is critically under-populated and requires remediation before a repurposing decision can be made.

Quick Overview

Item	Content
Original Indication	Not available (no regulatory record found)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction only; no actual studies linked to this combination
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN repurposing prediction is available for this combination. Without a predicted indication, a mechanism-to-indication bridge analysis cannot be performed.

What is structurally known: the 10 components collectively cover fat-soluble vitamins (D3, E), water-soluble vitamins (C, B6, B9, B12), an omega-3 fatty acid (DHA/Doconexent), and essential minerals (iron, calcium, magnesium). This profile is characteristic of prenatal or maternal nutritional support formulations, where the primary role is deficiency correction rather than disease modification.

Detailed mechanism of action (MOA) data is not available in the current evidence pack. Before any repurposing hypothesis can be formed, individual component MOAs should be retrieved from DrugBank and evaluated for disease-modifiable potential beyond nutritional supplementation.

Clinical Trial Evidence

Currently no related clinical trials are registered under this specific combination.

Literature Evidence

Currently no related literature is available for this multi-component combination as a unified entity.

Safety Considerations

Please refer to the package insert for safety information. All safety fields (key warnings, contraindications, drug-drug interactions) returned no data in this evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline produced no repurposing predictions for this combination, and the product has no US market authorization, no documented original indication, and no retrievable safety profile. There is no actionable evidence base from which to proceed.

To proceed, the following is needed:

Resolve Data Gap DG001 (Blocking): Retrieve package insert warnings and contraindications from the regulatory authority source (TFDA or FDA label database) to enable safety pre-screening.
Resolve Data Gap DG002 (High): Query DrugBank API for each of the 10 individual components to populate MOA fields and enable mechanism-based hypothesis generation.
Re-run TxGNN pipeline: Once individual component DrugBank IDs are confirmed, re-run the KG and DL prediction pipelines at the component level (rather than as a single multi-ingredient string) — the current query likely failed to match because the concatenated INN string does not map to a single DrugBank node.
Clarify product identity: Confirm whether this combination corresponds to a specific branded product (e.g., a prenatal vitamin) and retrieve its NDA/ANDA history, if any, from the FDA Orange Book.
Scope the repurposing question: Determine whether the intent is to repurpose the combination as a whole, or to identify novel indications for one or more individual components (e.g., Doconexent/DHA for neurological conditions, Folic Acid for cancer chemoprevention).
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.